In vivo stimulation of vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element

Thrombosis and Haemostasis

Volumn 84, Issue 4, 2000, Pages 706-711

  Dichtl, W ^a   Ares, M P S ^a   Stollenwerk, M ^a   Giachelli, C M ^a   Scatena, M ^a   Hamsten, A ^a   Eriksson, P ^a   Nilsson, J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Hypertriglyceridemia; NF B like proteins; Plasminogen activator inhibitor 1; VLDL RE

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSCRIPTION FACTOR; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; ARTERY WALL; ARTICLE; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; LIPID STORAGE; MALE; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT;

EID: 0033789950     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614091     Document Type: Article

References (48)

1. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
2. Fibrinolytic factor and the risk of myocardial infarction or sudden death in patients with angina pectoris
3. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis
4. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects
5. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor
6. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells.
7. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon
8. Oxidized LDL and lysophosphatidylcholine stimulate PAI-1 expression in vascular smooth muscle cells.
9. Effects of native, triglyceride-enriched and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells
10. Lipoprotein (a) regulates plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells: A potential mechanism in thrombogenesis
11. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: Correlation with age and serum triglyceride concentration
12. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1.
13. Plasma triglyceride and coronary heart disease
14. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein
15. Hypertriglyceridemia and regulation of fibrinolytic activity
16. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL
17. Alterations of VLDL composition during alimentary lipemia
18. VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: Involvement of the VLDL receptor
19. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells
20. Lipolysis of very low density lipoproteins by heparan sulfate proteoglycan-bound lipoprotein lipase
21. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells
22. Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction
23. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarctions in patients characterized by coronary angiography
24. A very low density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia
25. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene
26. Very low density lipoprotein activates nuclear factor-κB in endothelial cells
27. An animal model to study local oxidation of LDL and its biological effects in the arterial wall
28. Regulatory sequences and protein-binding sites involved in the expression of rat plasminogen activator inhibitor-1 gene
29. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man
30. Protein measurement with the Folin phenol reagent
31. Isolation and characterization of vasoformative endothelial cells from rat aorta
32. Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein
33. High level expression of functional full length and truncated glucocorticoid receptor in Chinese hamster ovary cells. Demonstration of ligand-induced down-regulation of expressed receptor mRNA and protein
34. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations. A family study with part of the stanislas cohort
35. Genotype-specific transcriptional regulation of PAI-1 gene by insulin, hypertriglyceridemic VLDL, and Lp(a) in transfected, cultured human endothelial cells
36. Increased PAI-1 activity and PAI-1 antigen occurring with an oral fat load: Associations with PAI-1 genotype and plasma active TGF-β levels
37. Increased intramural expression of plasminogen activator inhibitor type 1 after ballon injury: A potential progenitor of restenosis
38. Retention of fluorescent-labeled chylomicron remnants within the intima of the arterial wall - Evidence that plaque cholesterol may be derived from post-prandial lipoproteins
39. Isolation and characterization of the rat plasminogen activator inhibitor-1 gene
40. Notoginsenoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-lethality in mice in vivo
41. Inhibition of NF-κB by pyrrolidine dithiocarbamate blocks endothelial cell activation
42. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression
43. Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor-1 in cultured HepG2 cells
44. The interaction of p62 with RIP links the atypical PKCs to NF-κB activation
45. Transforming growth factor β is sequestered into an inactive pool by lipoproteins
46. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene
47. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression